Question · asked by 1 review

Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo: At least 1 AE during treatment for mild baseline pain

What each review found

Finding	Effect	Studies	GRADE certainty
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo At least 1 AE during treatment for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults (2016) · Cochrane Headline outcomes only	no estimate extracted	Not reported	Moderate
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo At least 1 AE during treatment for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults (2013) · Cochrane Headline outcomes onlyearlier version CD008541.PUB2, superseded	no estimate extracted	Not reported	Moderate

Findings are shown side by side, never pooled across reviews.

The reviews

Review	Searched up to	Included studies	AMSTAR 2
Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults 2016 · Cochrane Headline outcomes only	Not reported	list not extracted yet	Not assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.